Related Experiment Video

Updated: May 29, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Vaccines Against Pneumonia: Current Updates

Madelyn Renzetti1, Ashley Losier2

  • 1Albert Einstein College of Medicine, Yale University, New Haven, CT, USA.

Clinics in Chest Medicine
|May 27, 2026
PubMed

Insights

Pneumonia, a leading cause of death, can be prevented by vaccines targeting common pathogens. However, low vaccination rates and hesitancy hinder pneumonia prevention efforts globally.

Area of Science:

  • Medicine
  • Infectious Diseases
  • Public Health

Background:

  • Pneumonia is a major global cause of mortality, affecting all age groups.
  • Viral and bacterial pathogens cause pneumonia, with incidence varying by age and immune status.
  • Existing vaccines target key pneumonia-causing pathogens like influenza, COVID-19, RSV, pneumococcus, pertussis, and Haemophilus influenzae type b.

Purpose of the Study:

  • To review the role of vaccines in preventing pneumonia.
  • To highlight the effectiveness of vaccinations in reducing pneumonia incidence and hospitalizations.
  • To identify barriers to vaccination, such as vaccine hesitancy.

Main Methods:

  • Literature review of studies on pneumonia pathogens and vaccines.
  • Analysis of vaccine efficacy data for pneumonia prevention.
  • Examination of factors influencing vaccination uptake.

Main Results:

  • Vaccines significantly reduce pneumonia infection and hospitalization rates.
  • Vaccination is a critical tool for controlling pneumonia globally.
  • Low vaccination rates and vaccine hesitancy are significant barriers to pneumonia prevention.

Conclusions:

  • Vaccination is a proven strategy to combat pneumonia mortality and morbidity.
  • Addressing vaccine hesitancy and improving access are crucial for enhancing pneumonia prevention.
  • Continued efforts are needed to increase global vaccination coverage against pneumonia-causing pathogens.

Keywords:
COVID-19Haemophilus influenzaePertussisPneumococcal pneumoniaPneumococcal pneumonia vaccinesRespiratory syncytial virus (RSV)Vaccination

More Related Videos

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness12:21

A Mouse Model for the Transition of Streptococcus pneumoniae from Colonizer to Pathogen upon Viral Co-Infection Recapitulates Age-Exacerbated Illness

Published on: September 28, 2022

Related Concept Videos

Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps: